← Leaderboards
Leo Einck
Sequella, Inc.
$3,287,911
Attributed
$3,287,911
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $728.3K · FY2010–15$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$3,287,911 · 6
By mechanism
R43$1,494,672 · 4
R44$1,064,900 · 1
R01$728,339 · 1
Top collaborators
No co-investigators on record.
Most similar at Sequella, Inc.
Same institution · by research overlap
- Marina N Protopopova$5,540,511
- Boris V Nikonenko$299,045
- Matthew Charles Mulvey$684,296
Others in their field
Top investigators on “Tuberculosis”
- Judith S. Currier · University Of California Los Angeles$301,722,065
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$297,204,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$267,912,117
- Lawrence Corey · Fred Hutchinson Cancer Center$255,939,398
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$200,192,298
- Sharon A Nachman · Johns Hopkins University$194,852,226
Research focus
TuberculosisMycobacterium TuberculosisBacterial AntigensDiagnosis Design /EvaluationClinical ResearchAntibioticsAntitubercular AgentsPharmaceutical PreparationsConsumable /Disposable Biomedical EquipmentSafetyIn VitroMultidrug ResistanceBacterial VirusBaseInfectionIn Vitro ActivityDoseDrug CandidateDrug ResistanceEvaluationClinical TrialsCommunicable Disease DiagnosisDrug KineticsIn Vivo
Grant awards (8)
Development of a New Diamine (SQ109) for the Treatment of C. difficile Infection$728,339
R01 · FY2015 · AI · contact PI
SQ109 for treatment of MDR-TB$299,797
R43 · FY2011 · AI · contact PI
SQ109 for treatment of MDR-TB$300,000
R43 · FY2010 · AI · contact PI
Commercial Development of the Bronx Box$262,183
R44 · FY2003 · AI
Commercial Development of the Bronx Box$802,717
R44 · FY2002 · AI
A New Tuberculin for the Diagnosis of Tuberculosis$300,000
R43 · FY2001 · AI
COMMERCIAL DEVELOPMENT OF THE BRONX BOX$294,875
R43 · FY2001 · AI
ELECTRONIC MONITORING OF COMPLIANCE WITH TB CHEMOTHERAPY$300,000
R43 · FY2000 · AI